Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $18.75

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $18.75.

A number of analysts have recently issued reports on the company. Rodman & Renshaw initiated coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price for the company. RODMAN&RENSHAW raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, December 20th. Canaccord Genuity Group lifted their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th.

Atara Biotherapeutics Trading Down 1.9 %

ATRA stock opened at $16.53 on Tuesday. Atara Biotherapeutics has a one year low of $6.50 and a one year high of $39.50. The firm has a 50-day moving average of $12.20 and a two-hundred day moving average of $9.78. The firm has a market capitalization of $95.21 million, a PE ratio of -0.64 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter last year, the company posted ($16.50) EPS. On average, equities research analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at about $53,000. Cubist Systematic Strategies LLC bought a new position in Atara Biotherapeutics during the second quarter valued at approximately $79,000. State Street Corp lifted its stake in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares during the last quarter. FMR LLC grew its position in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.